Saint Luke’s Cancer Institute
The team at Saint Luke’s Cancer Institute provides early detection, expert diagnosis, personalized treatment options, and survivorship support to every patient. It’s what Saint Luke’s calls precision medicine: the right treatment for the right patient at the right time.
We offer the region’s only precision oncology program for advanced cancers that’s staffed by clinical oncologists with expertise in genomic sequencing and computational biology. With our clinical trial agreement with the internationally recognized Washington University School of Medicine, we can offer more than 200 National Cancer Institute-sponsored clinical trials and industry-led studies to Saint Luke’s Cancer Institute patients.
Personalized Cancer Treatment
Saint Luke’s Cancer Institute offers options for patients at every stage in their cancer journey:
- Medical oncologists and hematologists who subspecialize in every type of cancer, including breast, lung, gastrointestinal, liver, brain, and colon
- Genomic sequencing and precision oncology services for advanced cancers
- A Multidisciplinary Breast Clinic where patients meet with a team of specialists in one comprehensive appointment
- The region’s largest network of 3-D mammography centers for early detection of the smallest tumors
- Nurse navigators who serve as patient resources and advocates through treatment and beyond
- Innovative surgeries for brain tumors
- Supportive Oncology and Rehabilitative Services program to help patients overcome the physical and emotional challenges that often follow diagnosis and treatment
- Radiation Oncology offering leading-edge technology at four convenient metro locations
Second Opinions
When it comes to potentially life-changing or lifesaving treatments, patients and their families often seek a second opinion. Second opinions can provide:
- Confirmation of a diagnosis
- More details about type of cancer and stage, which affect treatment options
- Perspective from subspecialized oncologists
If you started your cancer journey at another facility, the experts at Saint Luke’s Cancer Institute are available to review your records and provide a thoughtful second opinion, including personalized treatment options available at Saint Luke’s.
Classes and Events
- Gilda’s Club Kansas City
- Look Good Feel Better
- Breast Cancer Support Groups
- Nutrition for Cancer Survivorship
- Dr. Jeffrey Wieman Cancer Prevention Lecture Series
Clinical Trials Available at Saint Luke's
For more information about clinical trials at Saint Luke's Cancer Institute, call 816-932-2677.
Brain Cancer
An Expanded Access Protocol for the Treatment of Glioblastoma Multiforme in Patients With Already Manufactured DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen Who Have Screen-Failed Protocol 020221 Learn more
Breast Cancer
Development and Implementation of The Breast Cancer Collaborative Registry (BCCR) Learn more
Phase 1 Study of Mifepristone in Combination With Eribulin in Patients With Locally Advanced/Metastatic Breast or Other Specified Solid Tumors, With a Dose Expansion Cohort in Patients With Triple Negative Breast Cancer Learn more
A Phase 3 Randomized, Placebo-Controlled Trial of Carboplatin and Paclitaxel With or Without the PARP Inhibitor Veliparib (ABT-888) in HER2 Negative Metastatic or Locally Advanced Unresectable BRCA-Associated Breast Cancer Learn more
A Phase III Randomized Double-blind, Placebo Controlled Study of Alpelisib in Combination With Fulvestrant for Men and Postmenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment Learn more
A Randomized, Multicenter, Open Label Study of MM-302 Plus Trastuzumab vs. Chemotherapy of Physician's Choice Plus Trastuzumab in Anthracycline Naive Patients With Locally Advanced/Metastatic HER2-Positive Breast Cancer Learn more
A Phase II Study of Neratinib Alone and in Combination With Fulvestrant in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer Learn more
A Phase I Dose Escalation Study of POL6326 With Eribulin in Patients With Relapsed, Triple Negative and Hormone Refractory ER Positive Metastatic Breast Cancer Learn more
A Phase Ib Trial of LEE011 in Combination With Everolimus (RAD001) and Exemestane in the Treatment of Postmenopausal Women With Hormone Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer Learn more
A Phase I/II, Single Arm, Open-label Study of Ribociclib in Combination With Everolimus + Exemestane in the Treatment of Men and Postmenopausal Women With HR+, HER2- Locally Advanced or Metastatic Breast Cancer Following Progression on a CDK 4/6 Inhibitor Learn more
Hematology
A Phase 3, Multicenter, Randomized, Double-blind Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Placebo Plus Best Supportive Care in Subjects With Red Blood Cell Transfusion-dependent Anemia and Thrombocytopenia Due to IPSS Lower-risk Myelodysplastic Syndromes Learn more
Liver Cancer
HepatocellularA Phase Ib/II Clinical Study of BBI608 in Combination With Sorafenib, or BBI503 in Combination With Sorafenib in Adult Patients With Hepatocellular Carcinoma Learn more
Lung Cancer
A Phase III, Open-Label, Randomized Study of MPDL3280A (Anti-PD-L1 Antibody) In Combination With Carboplatin + Paclitaxel With or Without Bevacizumab Compared With Carboplatin + Paclitaxel + Bevacizumab In Chemotherapy-Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Learn more
A Phase III, Open-label, Multicenter, Randomized Study Evaluating the Efficacy and Safety of MPDL3208A (Anti-PDL-1 Antibody) in Combination With Carboplatin + Paclitaxel or MPDL3208A in Combination With Carboplatin + Nab-paclitaxel Versus Carboplatin + Nab-paclitaxel in Chemotherapy-naive Patients With Stage IV Squamous Non-small Cell Lung Cancer Learn more
A Phase III, Open-label, Randomized Study to Investigate the Efficacy and Safety of MPDL3280A (Anti-PD-L1 Antibody) Compared With Best Supportive Care Following Adjuvant Cisplatin-based Chemotherapy in PD-L1-Selected Patients With Completely Resected Stage IB-IIIA Non-small Cell Lung Cancer Learn more
A Phase 1b/2 Study of Tergenpumatucel-L (HyperAcute Lung) Immunotherapy in Combination With the IDO Pathway Inhibitor Indoximod and Docetaxel in Patients With Advanced Previously Treated Non-Small Cell Lung Cancer (NSCLS) Learn more
Miscellaneous
Efficacy and Safety of Rivaroxaban Prophylaxis Compared With Placebo in Ambulatory Cancer Patients Initiating Systemic Cancer Therapy and at High Risk for Venous Thromboembolism Learn more
View the Saint Luke's Cancer Institute 2019 Annual Report (PDF).
